Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: re3 who wrote (95510)	4/12/2002 3:57:49 PM
From: Yogizuna	Respond to of 132070

Only thing I can come up with is the hourly and weekly charts are very over sold now, so it may be a reasonable time period to buy some shares.... No guarantees though of course.

To: re3 who wrote (95510)	4/12/2002 4:19:20 PM
From: Knighty Tin	Read Replies (1) \| Respond to of 132070

Unfortunately, at least one birdie has been told he will get a load of buckshot in his tailfeathers if he doesn't cool it.

To: re3 who wrote (95510)	4/13/2002 11:53:31 AM
From: tom r. phillips	Read Replies (1) \| Respond to of 132070

from this bird re. VASO: it hiccupped on revenue and got battered last week, but i think there's now a ... uhm ... er ... a buying opportunity for a 2 to 5 year hold. (i bought back yesterday at 2.60 what i'd sold before the earnings report and added more to my long position.) in the conference call (available on replay), management gave guidance predicting revenue this quarter which would be a 34% increase year-to-year and nearly 50% over last quarter. they have secure patents and FDA approvals and the prospect for more indications (e.g., for chronic heart failure) is strong. Medicare now reimburses for the treatment and has recently increased reimbursements, making an investment in equipment more attractive to the hospitals, cardiologists, and GPs. 80% of patients who are treated improve significantly; 53% discontinue nitroglycerine use. there are anecdotal reports that the treatment may help diabetics with circulatory problems, Parkinson's patients, erectile dysfunction, and on and on. there have been no insider sales of stock for nearly two years. a look at the bios of the board of directors inspires confidence, FWIW. Tom